Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

Recent research has found that semaglutide injections, which also include controversial weight loss drug Ozempic, can reduce ...

Fewer patients experienced a first hospital admission for any indication and for serious adverse events while on semaglutide.

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Study participants were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide 2.4mg or placebo alongside standard of care. The primary endpoints for part 1 were resolution of ...

FRIDAY, Nov. 1, 2024 (HealthDay News) -- The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, ...

For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and ...

Researchers investigate the clinical efficacy of semaglutide in controlling urine albumin-to-creatinine ratio in overweight ...